MetaCap

Perrigo (PRGO) vs Arcus Biosciences (RCUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Perrigo (PRGO) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 26.1% versus a loss of 29.2%. Over five years, PRGO leads with a -57.8% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.21 billion), about 1.0 times the size, while Perrigo is growing revenue faster (-2.8% vs -4.3%).

Perrigo pays a dividend yielding 7.28%, while Arcus Biosciences does not currently pay one. Perrigo converts more of its revenue into profit, with a net margin of -33.5% versus -142.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PRGO+26.11%RCUS-29.16%
+47%+7%-33%
Nov 21, 20251 yearNov 20, 2026
PRGO-61.25%RCUS-67.15%
+9%-41%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PRGO versus RCUS key metrics
MetricPRGORCUS
Share price$15.94$15.62
Market cap$2.21B$2.25B
1-day change-0.62%-1.01%
YTD return+14.51%-34.45%
1-year return+26.11%-29.16%
5-year return-57.81%-66.31%
Forward P/E6.94—
EPS (TTM)$-12.47$-3.64
Dividend yield7.28%0.00%
Annual dividend$1.16$0.00
Revenue (latest FY)$4.25B$247.00M
Revenue growth (YoY)-2.75%-4.26%
Net income (latest FY)$-1.43B$-353.00M
Gross margin35.14%—
Operating margin-26.39%-156.28%
Net margin-33.51%-142.91%
52-week high$17.07$31.74
52-week low$9.23$15.56
Distance from 52-week high-6.62%-50.78%
Analyst consensusbuystrong_buy
Avg. price target upside+12.92%+162.48%
Average volume2.54M1.85M
Shares outstanding138.80M143.99M
Employees8,100601
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRGO has outperformed RCUS by 55.3 percentage points over the past year.
  • Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
  • Perrigo is more profitable, keeping -33.5 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.

About Perrigo

PRGO stock →

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

PRGO vs RCUS FAQ

Which is bigger, Perrigo or Arcus Biosciences?

Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.21B for Perrigo (PRGO).

Which stock has performed better over the past year, PRGO or RCUS?

PRGO returned +26.11% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Perrigo or Arcus Biosciences?

Perrigo pays a dividend yielding 7.28%, while Arcus Biosciences does not currently pay a regular dividend.

Are Perrigo and Arcus Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons